Open Label, Single Arm, Exploratory Phase I Clinical Trial to Evaluate Efficacy and Safety of Mycobacterium w (Mw) in BCG [Bacille Calmette-Guerin] Refractory Superficial Transitional Cell Carcinoma.
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Cadi 05 (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cadila Pharmaceuticals
- 09 Mar 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 09 Mar 2012 Actual end date Jul 2011 added as reported by ClinicalTrials.gov.
- 15 Feb 2012 Planned number of patients changed from 20 to 22 as reported by Clinical Trials Registry - India.